Abstract
A strategy of logical drug design (LDD) and its application to prion diseases are reviewed. LDD is primarily based on the localizability of a hot spot which initiates structural instability in the target protein. It is also based on the regulability of the hot spot by small compounds, their designabilty by a computer, their organic synthesizability and the specificity of their functions once administered to the biological organisms. Unification of localizability, regulability, producibility and specificity is the central theme of LDD. Theoretical foundation of LDD based on quantum theories is initially outlined. The localizability using nuclear magnetic resonance (NMR), the regulability by a medical chaperone, the synthesizability, and the functional specificity accomplished thus far, are then described.
Keywords: Logical drug design, quantum chemistry, prion, hot spot, medical chaperone.
Current Topics in Medicinal Chemistry
Title:Logical Design of Medical Chaperone for Prion Diseases
Volume: 13 Issue: 19
Author(s): Kazuo Kuwata
Affiliation:
Keywords: Logical drug design, quantum chemistry, prion, hot spot, medical chaperone.
Abstract: A strategy of logical drug design (LDD) and its application to prion diseases are reviewed. LDD is primarily based on the localizability of a hot spot which initiates structural instability in the target protein. It is also based on the regulability of the hot spot by small compounds, their designabilty by a computer, their organic synthesizability and the specificity of their functions once administered to the biological organisms. Unification of localizability, regulability, producibility and specificity is the central theme of LDD. Theoretical foundation of LDD based on quantum theories is initially outlined. The localizability using nuclear magnetic resonance (NMR), the regulability by a medical chaperone, the synthesizability, and the functional specificity accomplished thus far, are then described.
Export Options
About this article
Cite this article as:
Kuwata Kazuo, Logical Design of Medical Chaperone for Prion Diseases, Current Topics in Medicinal Chemistry 2013; 13 (19) . https://dx.doi.org/10.2174/15680266113136660171
DOI https://dx.doi.org/10.2174/15680266113136660171 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuropeptides and Other Chemical Mediators, and the Role of Anti-inflammatory Drugs in Primary Headaches
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Curcumin Activates Erythrocyte Membrane Acetylcholinesterase
Letters in Drug Design & Discovery Functional Neuroimaging of Sleep Disorders
Current Pharmaceutical Design Preface [Hot Topic: Perspective on VLA-4 Antagonists (Guest Editor: Jefferson W. Tilley)]
Current Topics in Medicinal Chemistry Antibodies Against Muscarinic Receptors in Breast Cancer: Agonizing Tumor Growth
Current Immunology Reviews (Discontinued) Meet the Editorial Board
CNS & Neurological Disorders - Drug Targets Synthesis and Biological Activity of Novel N-glucosides Containing Substituted Piperazine Moiety
Letters in Drug Design & Discovery Implication of Circadian Rhythms and Melatonin in Major Depressive Disorder: The Evidence Base for New Antidepressant Treatment
Current Psychiatry Reviews Health Care Providers’ Need for Child and Adolescent Mental Health (CAMH) Training in South Western Nigeria
Adolescent Psychiatry Editorial (Thematic Issue: Inhibition of Botulinum Neurotoxin BoNT/A)
Current Topics in Medicinal Chemistry Design, Synthesis and Evaluation of 2,4,6-substituted Pyrimidine Derivatives as BACE-1 Inhibitor: Plausible Lead for Alzheimer’s Disease
Medicinal Chemistry Epigenetics and Periodontal Disease: Hope to Tame the Untameable
Current Gene Therapy Meet Our Associate Editor
Current Drug Delivery An Update on the Role of Matrix Metalloproteinases in the Pathogenesis of Multiple Sclerosis
Medicinal Chemistry Endocannabinoids in the Treatment of Mood Disorders: Evidence from Animal Models
Current Pharmaceutical Design Advanced Mass Spectrometry-Based Methods for the Analysis of Conformational Integrity of Biopharmaceutical Products
Current Pharmaceutical Biotechnology An Overview of Neolignans of the Genus Piper L.: Isolation Methods and Biological Activities
Mini-Reviews in Medicinal Chemistry Toxicokinetics in Drug Development: An Overview of Toxicokinetic Application in the Development of PNU-101017, an Anxiolytic Drug Candidate
Current Drug Metabolism Anti-Inflammatory Drugs in Psychiatry
Inflammation & Allergy - Drug Targets (Discontinued) Physical Activity as a Moderator of Alzheimer Pathology: A Systematic Review of Observational Studies
Current Alzheimer Research